Key Dates

None

National Cancer Institute (NCI)

The National Cancer Institute (NCI) intends to issue a U10 NCI National Clinical Trials Network (NCTN) – Canadian Collaborating Clinical Trials Network notice of funding opportunity (NOFO). The NCTN Canadian Collaborating Clinical Trials Network will be a full partner with the U.S. Network in the conduct of large-scale, multi-site clinical trials and help provide regulatory expertise/oversight for the conduct of NCTN trials in Canada. This. The primary goal of the NCTN is the conduct of multi-center, late-phase, clinical treatment trials (i.e., randomized phase 2 and phase 3 trials) and advanced imaging trials across a broad range of cancers, modalities, and diverse patient populations with relevance to the U.S. patient population as part of the NCI's overall clinical research program for adults, adolescents and young adults, and children with cancer. The NCTN also conducts umbrella/basket trials and rare tumor trials, when an extensive, national patient catchment area is required.

This Notice of Intent to Publish is being provided to allow sufficient time for the applicant to develop a strong application.
The NOFO is expected to be published in Fall 2024 with only one expected application due date in late February 2025.
 

This Notice encourages Canadian investigators with clinical cancer treatment trial expertise in adult oncology to begin to consider applying for this NOFO. The funding provides support for the organizational, administrative, and scientific management of the Canadian Collaborating Clinical Trials Network (CCCTN) with respect to the oversight of conduct of NCTN trials in Canadan and to the collective management of the overall NCTN Program. This funding support also extends to the Canadian Collaborating Clinical Trials Network, on occasion, leading large, multi-site NCTN cancer treatment trials that are also relevant to the U.S. patient population. The funding provides support for robust clinical trial statistical analysis plans as well as appropriate data management, serious adverse event reporting, and monitoring of all aspects of clinical trial conduct for the NCTN trials that the CCCTN participates in and/or leads, including support for Canadian site accrual and ensuring timely trial completion and data validity.

Funding Information

Applications are not being solicited at this time. 

Inquiries

Please direct all inquiries to:

Margaret Mooney, M.D.
National Cancer Institute (NCI)
Telephone: 240-276-6006
Email: NCINCTNRFA@mail.nih.gov